Ada Okafor sets down the jollof rice and says, before anyone can ask, “The scan was clean.” Nobody breathes out yet — fourteen months post-treatment, “clean” is still a word the whole table has to test before it believes it. Her daughter Uche exhales anyway. Across the table, Mateo just nods and passes the plantain, the way he does most things he’s relieved about but won’t perform.

This is the routine now: Sunday dinner, quarterly scans, a low hum of vigilance nobody names out loud. Ada’s oncologist mentioned something new at the last appointment — a blood test, not a scan, that could catch any recurrence months before an image would show it. It’s part of a bigger surveillance program, built by two testing companies that recently combined forces, each bringing a piece the other didn’t have. The doctor called it the most sensitive option available. She didn’t say what it costs, or whether insurance would touch it yet.

Uche has already decided. She wants her mother on it — now, this cycle, whatever it takes. She’s the one who drove Ada to every infusion, who still flinches at the hospital smell. Peace of mind isn’t a line item to her.

Mateo isn’t arguing against the science. He runs three bays and two mechanics on margins thin enough that one bad month means dipping into the account earmarked for Amara’s spring tuition and Diego’s tournament fees. He watched a supplier once promise him the better part, the newer way, and then watched the delivery slip for three months while his shop ate the difference. He’s not against the leap. He’s against taking it blind.

It’s Amara, home from her first year of pre-med, who reopens the whole thing without meaning to. She’s got a research assignment on liquid biopsy testing and reads a paragraph out loud at the table, a little proud of the vocabulary — not realizing she’s just described the exact test her grandmother’s doctor mentioned days earlier. Ada goes quiet. Uche looks at Mateo. Diego, mostly interested in his phone and the last plate of jollof, looks up because everyone else did.

“Is that the same one Dr. Patel talked about?” Amara asks, and just like that, the conversation nobody planned to have is the only one happening.

Nobody’s wrong here. That’s what makes it hard. Uche’s instinct — don’t wait, don’t gamble with time you can’t get back — is the instinct of someone who already lived the alternative. Mateo’s instinct — get the terms in writing before you commit the money — is the instinct of someone who’s been burned trusting a promise before the paperwork caught up. Ada just wants the decision to not cost her family anything, financially or otherwise, which is its own quiet, impossible ask.

They don’t solve it over dinner. What they land on, plates half-cleared, is smaller and more useful than a decision: Uche will call the insurance company first thing Monday. Not “should we do this” — just “what would it actually cost, and when.” Get the real number before arguing about what to do with it. Mateo relaxes, visibly. It isn’t no. It’s not yet.

There’s something almost boringly wise about that instinct, and it’s the same one worth sitting with if you’ve been watching Tempus AI (TEM) lately. The company just made its own version of the Okafor-Reyes bet — a bold, expensive move to combine forces and catch what matters earlier, announced right as the market demanded to know exactly what it would cost and when it would close. Wall Street didn’t wait for its own Monday call. It sold first and asked questions never.

We think there’s a version of “get the real number before you argue about what to do with it” worth applying here too. Not blind faith in the promise. Not walking away from a technology that’s actually working. Just — wait for the terms.

Part 2, publishing Tuesday, is where we do exactly that: the entry zones, the risk still hanging over the deal, and the actual number we’re waiting to hear before sizing a position.